title: The effect of lansoprazole treatment on the healing and relapse of peptic ulcer and serum levels of IgG anti-Helicobacter pylori antibody.
abstract: In the present study, the effects of short-term treatment with lansoprazole on healing and recurrence of peptic ulcer were investigated. Complete healing (change to the S2 stage) after 3 or 4 weeks of treatment with lansoprazole was observed in 9.9% of gastric ulcers and 38.3% of duodenal ulcers. Complete healing was observed after 3 or 4 weeks of treatment with lansoprazole in gastric ulcers and was significantly related to the serum titer of IgG anti-Helicobacter pylori antibodies. This was not the case in duodenal ulcers. Complete healing after 6 or 8 weeks of treatment with lansoprazole was not dependent on serum levels of IgG anti-H. pylori antibodies. Short-term treatment by lansoprazole did not affect serum levels of IgG anti-H. pylori antibodies immediately after the end of lansoprazole treatment, but significantly reduced serum levels of IgG anti-H. pylori antibodies were found 9 months after treatment.
authors.affiliation: Department of Gastroenterology, University of Tokyo, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Mine
authors.forename: H
authors.initials: H
authors.lastname: Yasuda
authors.forename: K
authors.initials: K
authors.lastname: Akimoto
authors.forename: A
authors.initials: A
authors.lastname: Katoaka
authors.forename: H
authors.initials: H
authors.lastname: Mashima
authors.forename: A
authors.initials: A
authors.lastname: Tajima
authors.forename: H
authors.initials: H
authors.lastname: Fukujin
authors.forename: T
authors.initials: T
authors.lastname: Tsuchida
authors.forename: T
authors.initials: T
authors.lastname: Takano
authors.forename: J
authors.initials: J
authors.lastname: Nagasawa
mesh_terms: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000897:Anti-Ulcer Agents / Q000627:therapeutic use*; D000907:Antibodies, Bacterial / Q000032:analysis*; D004381:Duodenal Ulcer / Q000188:drug therapy / Q000276:immunology / Q000503:physiopathology; D005260:Female; D016480:Helicobacter pylori / Q000276:immunology*; D006801:Humans; D007074:Immunoglobulin G / Q000032:analysis*; D064747:Lansoprazole; D008297:Male; D008875:Middle Aged; D009853:Omeprazole / Q000031:analogs & derivatives* / Q000627:therapeutic use; D010437:Peptic Ulcer / Q000188:drug therapy* / Q000276:immunology / Q000503:physiopathology; D054328:Proton Pump Inhibitors; D012008:Recurrence; D013276:Stomach Ulcer / Q000188:drug therapy / Q000276:immunology / Q000503:physiopathology
chemical_list: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000897:Anti-Ulcer Agents; D000907:Antibodies, Bacterial; D007074:Immunoglobulin G; D054328:Proton Pump Inhibitors; D064747:Lansoprazole; D009853:Omeprazole